New York State Approves Precipio’s HemeScreen for POL clinical use
18 nov. 2021 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
26 août 2021 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
20 janv. 2021 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US,...
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
10 déc. 2020 10h15 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...
Precipio Adds Another HemeScreen™ Customer
09 juin 2020 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 09, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted...
Precipio Launches New HemeScreen™ Reagent Rental Program
06 avr. 2020 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 06, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program....
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™
30 sept. 2019 11h10 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...
Precipio’s HemeScreen™ Adopted by Methodist Health
03 avr. 2019 07h38 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected...
Precipio Files Patent for HemeScreen™, its Novel Molecular Assay
08 janv. 2019 07h45 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the filing of a patent for its proprietary HemeScreen panel....
Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
03 oct. 2018 07h47 HE
|
Precipio, Inc.
Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...